To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in North America (the United States of America (USA) and Mexico).
The trial is designed to evaluate the effects of treatment with liraglutide versus
glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind
trial period plus a 52-week open-label extension (week 104) followed by an additional
156-week continued open-label extension. The total duration of the treatment period is
planned to be 260 weeks (5 years).